For Research Use Only · Not For Human or Veterinary Use · Not FDA-Approved

— Research monograph

Sermorelin

GHRH(1-29)sermorelin acetate

The 29-amino-acid active fragment of growth-hormone-releasing hormone.

Updated

Class
GHRH receptor agonist — 29-amino-acid fragment of growth-hormone-releasing hormone
Half-life (research)
~10–20 min (rapid serum clearance is characteristic of GHRH analogs).
Origin
The shortest N-terminal fragment of GHRH retaining full biological activity at GHRH receptors. Synthesized and characterized following identification of full-length GHRH by Guillemin and colleagues in the early 1980s.
Solubility
Highly water-soluble. Physicochemical context only. Merit Sciences publishes no reconstitution or preparation procedures.

What is Sermorelin?

Sermorelin is the synthetic acetate salt of GHRH(1-29), the N-terminal 29 amino acids of human growth-hormone-releasing hormone (somatocrinin). It is the shortest GHRH fragment known to retain full intrinsic activity at the GHRH receptor and is among the most-studied secretagogues in the public research literature.

Unlike growth hormone itself, sermorelin acts upstream by stimulating endogenous pituitary GH release in a physiologic pulsatile pattern, preserving negative-feedback regulation by somatostatin and IGF-1.

How does Sermorelin work?

Selective agonist at the GHRH receptor on anterior pituitary somatotrophs. Receptor activation triggers cAMP-mediated calcium influx and stimulates pulsatile growth hormone release from pituitary stores.

Research applications

  • GH / IGF-1 axis research
  • Pituitary somatotroph function
  • GHRH receptor pharmacology
  • Comparative secretagogue studies

Sermorelin at Merit

Research review on The Assay, Merit’s editorial publication: Tesamorelin vs Sermorelin: One Approved, One Discontinued

Research review on The Assay, Merit’s editorial publication: Ipamorelin vs Sermorelin vs CJC-1295: What the Published Research Compares

Form & storage

Sermorelin ships as a sealed, lyophilized (freeze-dried) powder. Highly water-soluble. Physicochemical context only. Merit Sciences publishes no reconstitution or preparation procedures. Store sealed, light-protected, and follow your institution’s handling procedures for research materials.

Frequently asked questions

What is Sermorelin?

Sermorelin is the synthetic acetate salt of GHRH(1-29), the N-terminal 29 amino acids of human growth-hormone-releasing hormone (somatocrinin). It is the shortest GHRH fragment known to retain full intrinsic activity at the GHRH receptor and is among the most-studied secretagogues in the public research literature. Merit supplies it as a lyophilized research compound for research use only, not for human or veterinary use.

How does Sermorelin work?

Selective agonist at the GHRH receptor on anterior pituitary somatotrophs. Receptor activation triggers cAMP-mediated calcium influx and stimulates pulsatile growth hormone release from pituitary stores. Mechanistic descriptions summarize published preclinical findings and are not clinical claims.

What is the half-life of Sermorelin?

~10–20 min (rapid serum clearance is characteristic of GHRH analogs). Values reflect preclinical or research-context reports, not clinical pharmacokinetics.

Is Merit Sermorelin for human use?

No. It is sold strictly for research use only: not for human or veterinary use, and not for diagnostic or therapeutic use.

Is Sermorelin FDA-approved?

Sermorelin was FDA-approved as Geref, which its sponsor discontinued in 2008; in 2013 FDA determined it was not withdrawn for reasons of safety or effectiveness. Research material sold as sermorelin is not FDA-approved. Supplied for research use only. Sermorelin is named on the WADA 2026 Prohibited List under S2 as a growth hormone releasing hormone analogue and is prohibited at all times.

How is each batch of Sermorelin tested?

Every Merit batch is tested by an independent laboratory for identity and HPLC purity before it is listed, and Merit identifies batches by date rather than by lot number. Published certificates are in the COA library at meritsciences.com/coa, searchable by compound.

Regulatory status checked October 22, 2026 against: Federal Register, Drugs@FDA, WADA Prohibited List.

References

  1. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. Walker RF. Clinical Interventions in Aging, 2006 · PMID 18046908
  2. Sermorelin: a synthetic growth hormone-releasing hormone analogue. Pharmacology and clinical use. Prakash A, Goa KL. BioDrugs, 1999 · doi:10.2165/00063030-199912020-00007
  3. Growth-hormone-releasing hormone (1-29) in adults. Khorram O, Laughlin GA, Yen SS. Journal of Clinical Endocrinology and Metabolism, 1997 · PMID 9360512

For research use only. Not for human or veterinary use. Reference information summarized from published literature, not medical advice.